NOVAVAX INC Earnings Per Share (Diluted)
NOVAVAX INC (NVAX) reported Earnings Per Share (Diluted) of -$0.32 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- NOVAVAX INC earnings per share, diluted for the quarter ending 2026-06-30 was -$0.32, a 151.61% decline year-over-year.
- NOVAVAX INC earnings per share, diluted for the quarter ending 2026-03-31 was -$0.06, a 102.05% decline year-over-year.
- NOVAVAX INC earnings per share, diluted for the quarter ending 2025-12-31 was $0.09.
- NOVAVAX INC earnings per share, diluted for the quarter ending 2025-09-30 was -$1.25.
- NOVAVAX INC earnings per share, diluted for fiscal 2025 was $2.58.
- NOVAVAX INC earnings per share, diluted for fiscal 2024 was -$1.23.
- NOVAVAX INC earnings per share, diluted for fiscal 2023 was -$5.41.
- NOVAVAX INC earnings per share, diluted for fiscal 2022 was -$8.42.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.32 10-Q · filed 2026-08-06 | -$0.38 10-Q · filed 2026-08-06 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.46 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.06 10-Q · filed 2026-05-06 | $0.05 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | $0.09 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.58 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.25 10-Q · filed 2025-11-06 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.53 10-Q · filed 2025-11-06 | $2.02 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | $0.62 10-Q · filed 2026-08-06 | $3.55 10-Q · filed 2026-08-06 | $3.17 derived: net income ÷ weighted average shares · filed 2026-08-06 | $2.50 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | $2.93 10-Q · filed 2026-05-06 | $2.59 derived: net income ÷ weighted average shares · filed 2026-05-06 | $1.91 derived: net income ÷ weighted average shares · filed 2026-05-06 | $2.88 derived: net income ÷ weighted average shares · filed 2026-05-06 |
| 2024-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$1.23 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.76 10-Q · filed 2025-11-06 | $0.25 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.71 10-Q · filed 2025-11-06 | -$1.93 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2024-06-30 | $0.99 10-Q · filed 2025-08-06 | $0.10 10-Q · filed 2025-08-06 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.21 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2024-03-31 | -$1.05 10-Q · filed 2025-05-08 | -$2.47 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$3.73 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$3.38 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2023-12-31 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.72 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$2.27 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$5.41 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.26 10-Q · filed 2024-11-12 | -$0.70 derived: net income ÷ weighted average shares · filed 2024-11-12 | -$3.94 10-Q · filed 2024-11-12 | -$5.88 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2023-06-30 | $0.58 10-Q · filed 2024-08-08 | -$2.69 10-Q · filed 2024-08-08 | -$4.65 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$6.74 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2023-03-31 | -$3.41 10-Q · filed 2024-05-10 | -$5.74 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$7.92 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$14.33 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2022-12-31 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$4.44 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$10.94 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$8.42 10-K · filed 2025-02-27 |
| 2022-09-30 | -$2.15 10-Q · filed 2023-11-09 | -$8.68 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$6.13 10-Q · filed 2023-11-09 | -$16.90 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2022-06-30 | -$6.53 10-Q · filed 2023-08-08 | -$3.97 10-Q · filed 2023-08-08 | -$14.75 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$19.09 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2022-03-31 | $2.56 10-Q · filed 2023-05-09 | -$8.22 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$12.53 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$17.27 derived: net income ÷ weighted average shares · filed 2026-04-27 |
| 2021-12-31 | -$11.18 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$15.54 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$20.32 derived: net income ÷ weighted average shares · filed 2026-04-27 | -$23.44 10-K · filed 2024-02-28 |
| 2021-09-30 | -$4.31 10-Q · filed 2021-11-05 | -$9.07 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$12.13 10-Q · filed 2021-11-05 | -$14.95 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-06-30 | -$4.75 10-Q · filed 2021-08-05 | -$7.82 10-Q · filed 2021-08-05 | -$10.60 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$13.84 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-03-31 | -$3.05 10-Q · filed 2022-05-10 | -$5.77 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$8.95 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$9.50 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$2.70 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$5.89 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$6.33 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$7.27 10-K · filed 2023-02-28 |
| 2020-09-30 | -$3.21 10-Q · filed 2021-11-05 | -$3.58 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$4.39 10-Q · filed 2021-11-05 | |
| 2020-06-30 | -$0.30 10-Q · filed 2021-08-05 | -$0.84 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | -$5.51 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |